TW202203914A - 特別用於治療b型肝炎和d型肝炎之抗病毒化合物 - Google Patents

特別用於治療b型肝炎和d型肝炎之抗病毒化合物 Download PDF

Info

Publication number
TW202203914A
TW202203914A TW110109839A TW110109839A TW202203914A TW 202203914 A TW202203914 A TW 202203914A TW 110109839 A TW110109839 A TW 110109839A TW 110109839 A TW110109839 A TW 110109839A TW 202203914 A TW202203914 A TW 202203914A
Authority
TW
Taiwan
Prior art keywords
optionally substituted
group
alkyl
aryl
heteroaryl
Prior art date
Application number
TW110109839A
Other languages
English (en)
Chinese (zh)
Inventor
台生 宋
Original Assignee
生華生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 生華生物科技股份有限公司 filed Critical 生華生物科技股份有限公司
Publication of TW202203914A publication Critical patent/TW202203914A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW110109839A 2020-03-30 2021-03-18 特別用於治療b型肝炎和d型肝炎之抗病毒化合物 TW202203914A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063001723P 2020-03-30 2020-03-30
US63/001,723 2020-03-30
US202063053908P 2020-07-20 2020-07-20
US63/053,908 2020-07-20

Publications (1)

Publication Number Publication Date
TW202203914A true TW202203914A (zh) 2022-02-01

Family

ID=77920792

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110109839A TW202203914A (zh) 2020-03-30 2021-03-18 特別用於治療b型肝炎和d型肝炎之抗病毒化合物
TW110109844A TW202203915A (zh) 2020-03-30 2021-03-18 特別用於治療新冠肺炎之抗病毒化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110109844A TW202203915A (zh) 2020-03-30 2021-03-18 特別用於治療新冠肺炎之抗病毒化合物

Country Status (11)

Country Link
US (2) US20210308137A1 (https=)
EP (2) EP4126846A1 (https=)
JP (2) JP2023520883A (https=)
KR (2) KR20230004550A (https=)
CN (1) CN116075502B (https=)
AU (2) AU2021249224A1 (https=)
BR (2) BR112022019558A2 (https=)
CA (2) CA3179167A1 (https=)
IL (2) IL296927B2 (https=)
TW (2) TW202203914A (https=)
WO (2) WO2021202114A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102641010B1 (ko) 2023-12-04 2024-02-28 대한민국 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
CN101528704B (zh) * 2006-09-01 2014-04-09 生华生物科技股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
JP2011515337A (ja) * 2008-02-29 2011-05-19 サイレーン ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼモジュレーター
KR20120044281A (ko) * 2009-04-17 2012-05-07 사일린 파마슈티칼스, 인크 단백질 키나제 ｃｋ2 활성과 관련된 장애의 치료 방법
US20110071136A1 (en) * 2009-09-16 2011-03-24 Cylene Pharmaceuticals, Inc Novel tricyclic protein kinase modulators
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
JP5802676B2 (ja) * 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
TWI534148B (zh) * 2014-02-13 2016-05-21 生華生物科技股份有限公司 吡唑並嘧啶前藥及其使用方法
CN105457029A (zh) * 2014-09-29 2016-04-06 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
WO2021195126A1 (en) * 2020-03-24 2021-09-30 Burnet Michael W Anti-infective and anti-viral compounds and compositions
WO2021247367A1 (en) * 2020-06-02 2021-12-09 Yale University Compounds and compositions for treating, ameliorating, and/or preventing sars-cov-2 infection and/or complications thereof

Also Published As

Publication number Publication date
CN116075502A (zh) 2023-05-05
EP4126846A1 (en) 2023-02-08
CA3179167A1 (en) 2021-10-07
AU2021249224A1 (en) 2022-12-01
IL296927B1 (en) 2025-07-01
US20210308110A1 (en) 2021-10-07
WO2021202114A1 (en) 2021-10-07
WO2021202115A1 (en) 2021-10-07
EP4126845A4 (en) 2024-05-01
US20210308137A1 (en) 2021-10-07
BR112022019554A2 (pt) 2022-12-06
CA3179372A1 (en) 2021-10-07
CN116075502B (zh) 2024-04-12
KR20230004550A (ko) 2023-01-06
JP2023520882A (ja) 2023-05-22
TW202203915A (zh) 2022-02-01
AU2021248867A1 (en) 2022-12-01
IL296924A (en) 2022-12-01
US11696911B2 (en) 2023-07-11
EP4126845A1 (en) 2023-02-08
KR20230004549A (ko) 2023-01-06
JP2023520883A (ja) 2023-05-22
BR112022019558A2 (pt) 2022-12-06
IL296927B2 (en) 2025-11-01
IL296927A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
JP6516705B2 (ja) Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
JP6285440B2 (ja) 融合二環式スルファモイル誘導体並びにｂ型肝炎の治療のための薬剤としてのその使用
JP7101663B2 (ja) Ｔｌｒ７アゴニストとｈｂｖキャプシドアセンブリ阻害剤の併用療法
WO2017108630A1 (en) Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
BR112021000938A2 (pt) composto sal farmaceuticamente aceitável, tautômero, isômero ou estereoisômero do mesmo, composição farmacêutica e processo para a síntese do dito composto
WO2020016434A1 (en) Cyclic inhibitors of hepatitis b virus
TW202203914A (zh) 特別用於治療b型肝炎和d型肝炎之抗病毒化合物
JP2022519764A (ja) 二環式スルホンアミド
JP2025507472A (ja) ケトアミド系誘導体及びその製薬における使用
JP2021503466A (ja) 抗ＨＢＶのテトラヒドロイソキサゾロ［４，３−ｃ］ピリジン類化合物
CN116761598A (zh) Fabp4调节化合物的抗病毒用途
US12138243B2 (en) Antiviral use of FABP4 modulating compounds
EP3628663A1 (en) Antiviral compounds
JP2023513711A (ja) Ｂ型肝炎ウイルスのスピロ環式阻害剤
HK40086507A (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
WO2025011656A1 (en) Anticoronviral compounds and compositions and uses thereof
HK40086507B (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
WO2021228222A1 (zh) 用于治疗乙肝的组合
EP3825318A1 (en) Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
CN116178367A (zh) 苯并杂环类化合物在治疗或预防乙型肝炎中的应用
BR112017019758B1 (pt) Tratamento combinado com um agonista de tlr7 e um inibidor de montagem de capsídeo de hbv
BR112020006456B1 (pt) Compostos químicos, composição farmacêutica e seus usos para tratar uma infecção por vírus da hepatite b e para inibir o nível do antígeno hbe ou hbs em um hbsag de mamífero in vitro
BR122021002683B1 (pt) Tratamento combinado com um agonista de tlr7 e um inibidor de montagem de capsídeo de hbv
JP2018521107A (ja) Ｈｉｖ感染を予防または治療するためのベツイン誘導体